Unicycive Therapeutics Inc Ordinary Shares UNCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY
-
Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY
-
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
-
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
-
UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026
-
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
-
UNCY UPCOMING DEADLINE: Levi & Korsinsky Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
-
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
Trading Information
- Previous Close Price
- $3.70
- Day Range
- $3.56–3.71
- 52-Week Range
- $3.56–8.74
- Bid/Ask
- $3.56 / $3.97
- Shares Outstanding
- 27.86M
- Market Cap
- $100.00M
- Volume/Avg
- 896,236 / 847,651
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.unicycive.com
Valuation
|
Metric
|
UNCY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.95 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
UNCY
|
|---|---|
Quick Ratio | 3.28 |
Current Ratio | 3.81 |
Interest Coverage | −872.57 |
Quick Ratio
UNCY
Profitability
|
Metric
|
UNCY
|
|---|---|
Return on Assets (Normalized) | −49.93% |
Return on Equity (Normalized) | −75.91% |
Return on Invested Capital (Normalized) | −78.70% |
Return on Assets
UNCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|fT!^^<Q | LOCK|hC>z | $129B | |||
| Moderna Inc
MRNA
| LOCK|!Q$!D> | LOCK|>x | $94B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|D%jK@r$ | LOCK|Y$?! | $82B | |||
| argenx SE ADR
ARGX
| LOCK|k%%nQhW | LOCK|pc | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|F!CgB?v | LOCK|@N^ | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$sh%K! | LOCK|$?g< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@lx!Nvv | LOCK|@^qHd | $27B | |||
| Incyte Corp
INCY
| LOCK|$>wN<m | LOCK|zM< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|H>r@X^ | LOCK|MdN | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|qYnC^t | LOCK|!k | $14B |
United States